463 related articles for article (PubMed ID: 20221443)
1. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
[TBL] [Abstract][Full Text] [Related]
2. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
[TBL] [Abstract][Full Text] [Related]
3. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
[TBL] [Abstract][Full Text] [Related]
4. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
6. BST-2/tetherin: a new component of the innate immune response to enveloped viruses.
Evans DT; Serra-Moreno R; Singh RK; Guatelli JC
Trends Microbiol; 2010 Sep; 18(9):388-96. PubMed ID: 20688520
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.
Iwabu Y; Fujita H; Kinomoto M; Kaneko K; Ishizaka Y; Tanaka Y; Sata T; Tokunaga K
J Biol Chem; 2009 Dec; 284(50):35060-72. PubMed ID: 19837671
[TBL] [Abstract][Full Text] [Related]
8. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
9. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
10. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
11. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
Neil SJ; Zang T; Bieniasz PD
Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
[TBL] [Abstract][Full Text] [Related]
12. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
13. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
14. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
15. [Inhibition of HIV virus-like particles production by BST-2].
Du YL; Hu SQ; Pang XJ; Cen S; Jin Q; Guo F
Bing Du Xue Bao; 2011 Jul; 27(4):319-25. PubMed ID: 21874899
[TBL] [Abstract][Full Text] [Related]
16. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
17. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu.
Andrew AJ; Miyagi E; Kao S; Strebel K
Retrovirology; 2009 Sep; 6():80. PubMed ID: 19737401
[TBL] [Abstract][Full Text] [Related]
18. Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.
Miyagi E; Andrew AJ; Kao S; Strebel K
Proc Natl Acad Sci U S A; 2009 Feb; 106(8):2868-73. PubMed ID: 19196977
[TBL] [Abstract][Full Text] [Related]
19. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
[TBL] [Abstract][Full Text] [Related]
20. The great escape: viral strategies to counter BST-2/tetherin.
Douglas JL; Gustin JK; Viswanathan K; Mansouri M; Moses AV; Früh K
PLoS Pathog; 2010 May; 6(5):e1000913. PubMed ID: 20485522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
